Creating the
Next Frontier of Immunotherapies
Aakha Bio is revolutionizing immune therapies
In Assamese, Aakha means Hope. ​
At Aakha, we are transforming that hope into reality by developing new treatments for patients with limited options.​
​​​
We are building first-in-class, multi-specific antibodies for solid tumors that efficiently block disease-driver pathways & engage in optimal immune activation
​
With a modular, multi-pronged platform, our antibodies integrate multiple synergistic mechanisms into a single molecule, creating powerful, elegant therapeutic solutions.
Activated T cells
Activated NK cells
Tumor cell
Activating NK cells & cytotoxic T cells releases tumor- killing toxins
Meet the dedicated team behind Aakha Biologics
Hemanta Baruah, PhD
Founder & CEO
An experienced drug developer with an approved checkpoint inhibitor & several candidates in advanced clinical trials.
Errik Anderson
Board Member
Founder & CEO of Alloy Therapeutics. Serial biotech entrepreneur including co-founding Adimab, Alector, Arsanis, Avitide, and Compass Therapeutics.
Chris Pacheco, PhD
Board Member
VP, Head of Venture Partnerships at Ginkgo Bioworks. Formerly at 82VS, Polaris Partners, Roche Diagnostics, and the Whitehead Institute.
Robert Mabry, PhD
Board Member
CEO at Hillstar Bio. Formerly
at Orna Therapeutics, Takeda Pharmaceuticals, Cogen Therapeutics, Jounce Therapeutics, and Adimab.
Katie Hewitt
CBO
Over 25 years of business development experience at Eli Lilly. Deep expertise in biotech deal structuring, licensing negotiations, M&A, and strategic partnership execution across therapeutic modalities.
Manoj Sabnani
Senior Scientist
Formerly at Alloy Therapeutics, lab coordinator at University of Texas Arlington, researcher at Texas Tech University Health Sciences Center and Purdue University Calumet.
Ugur Eskiocak, PhD
SAB Member
CEO & Co-Founder at Voro Therapeutics. Experienced cancer biologist and immunologist.
SAB & Advisors
Michele Ardolino, PhD
SAB Member
Associate Professor, Biochemistry, Microbiology, Immunology at Ottawa Hospital Research Institute
Jeanette Boudreau, PhD
SAB Member
Professor at Dalhousie University and the Scientific Director of the Beatrice Hunter Cancer Research Institute
Darshan Gandhi, MD, MBA
Clinical Advisor
Hematologist & Oncologist at the Methodist Health System in Dallas, TX.
Esra Akbay, PhD
Academic Advisor
Associate Professor, Pathology at UT Southwestern Medical Center
Pipeline of First-in-Class Drugs
Program 1, Solid Tumors
Anti-MICA x CD3
Bispecific T-Cell Engager
Discovery
Lead Op
IND-enabling
Phase 1
Program 2, Solid Tumors
Anti-EGFR x cMET x NKA*
Trispecific N-Cell Engager
*NK-cell activating target
Our Investors
Incubated at 82VS, Alloy Therapeutics’ affiliated venture studio, Aakha was created through a collaborative partnership model that leverages access to Alloy’s ATX-Gx™ transgenic mouse, suite of antibody discovery platforms, and discovery services.
